A Registry for Patients Taking Uptravi

a study on High Blood Pressure Pulmonary Arterial Hypertension

Summary

for people ages 18-99 (full criteria)
at La Jolla, California and other locations
study started
estimated completion

Description

Summary

This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.

Official Title

Uptravi® (SelexiPag): tHe usErs dRug rEgistry

Keywords

Pulmonary Arterial Hypertension Hypertension Familial Primary Pulmonary Hypertension Selexipag

Eligibility

You can join if…

Open to people ages 18-99

  • Signed patient informed consent form (ICF).
  • Patients ≥ 18 years of age at time of Uptravi initiation, and
  • Patients who initiate Uptravi:
  • at enrollment, or
  • less than or equal to 60 days prior to enrollment and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and dates and highest tolerated dose and dates)

You CAN'T join if...

  • Patients previously exposed to Uptravi treatment during a clinical trial.
  • Patients that previously discontinued Uptravi for any reason, prior to study enrollment (discontinuation defined as an interruption of therapy greater than or equal to 30 days).
  • Patients enrolled in a blinded clinical trial or in a clinical trial involving an unapproved drug.

Locations

  • University of California San Diego accepting new patients
    La Jolla California 92093 United States
  • LA Biomed Research Inst at Harbor UCLA Medical Center accepting new patients
    Torrance California 90502 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Actelion
ID
NCT03278002
Study Type
Observational [Patient Registry]
Last Updated